Consequently, ANRIL down-regulation strengthened the inhibitory effect of cisplatin on tumor growth, showing that silencing ANRIL can also enhance cisplatin-induced cytotoxicity and enhance cisplatin sensitivity in vivo. The gene discussed is CDKN2B-AS1; the disease is neoplasm.